Last updated: February 22, 2026
What is NDC 57896-0974?
NDC 57896-0974 corresponds to Ralinepag, an investigational oral prostacyclin receptor agonist developed by Reata Pharmaceuticals for pulmonary arterial hypertension (PAH). The drug aims to improve pulmonary vascular resistance and exercise capacity.
Market Overview
Current Market Landscape for PAH Treatments
- The global PAH market was valued at approximately $4.1 billion in 2021.
- The market is dominated by drugs targeting prostacyclin pathways, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors.
- Leading treatments include Remodulin (treprostinil), Adempas (riociguat), and Opsumit (macitentan).
Key Players & Competitive Products
| Product |
Class |
Market Share (2021) |
Price Range (per month) |
Approval Status |
| Remodulin |
Prostacyclin analogs |
40% |
$15,000 - $20,000 |
Approved |
| Opsumit |
Endothelin receptor antagonists |
25% |
$10,000 - $15,000 |
Approved |
| Adempas |
Soluble guanylate cyclase stimulator |
15% |
$12,000 - $18,000 |
Approved |
| Selexipag (Uptravi) |
Prostacyclin pathway agonist |
12% |
$14,000 - $19,000 |
Approved |
Unmet Needs and Market Potential
- Current therapies primarily focus on symptom management.
- Ralinepag's oral administration offers convenience over injectable prostacyclins.
- Estimated that at least 60,000 patients worldwide could benefit from new therapies in the PAH pipeline, with unmet needs in early-stage and treatment-resistant groups.
Regulatory Status and Development Timeline
- Clinical Phase III trials initiated in 2020.
- Pending data readouts expected in 2023-2024.
- No approved indication currently; commercialization dependent on NDA approval.
Price Projections
Cost Analysis and Pricing Strategy
- Oral prostacyclins are priced between $12,000 to $20,000 per month.
- The premium price aims to reflect the convenience and potentially improved patient adherence.
- A competitive launch price for Ralinepag could be set at $14,000 to $16,000 per month.
Revenue Forecasts
| Year |
Estimated Patients Treated |
Market Penetration |
Projected Revenue (USD) |
Notes |
| 2024 |
5,000 |
10% |
$84 million |
Launch year, conservative uptake |
| 2025 |
10,000 |
20% |
$168 million |
Increased adoption |
| 2026 |
15,000 |
30% |
$252 million |
Growing awareness |
| 2027 |
20,000 |
40% |
$336 million |
Expanded market penetration |
Price Sensitivity
- Slight reductions (~10%) in price could expand access but may impact revenue.
- Insurance reimbursement and formulary inclusion will influence retail price variations.
Risks and Market Entry Barriers
- Clinical trial success remains uncertain.
- Competition from marketed drugs with established safety profiles.
- Payer resistance to high-cost therapies may limit rapid adoption.
- Regulatory delays could shift revenue timelines.
Key Takeaways
- The PAH market is mature but still growing due to unmet needs.
- Ralinepag's oral route provides a competitive advantage.
- Pricing will likely fall within current prostacyclin analog ranges ($12,000 - $20,000/month).
- Market entry will depend on positive clinical results and regulatory approval.
- Revenue potential ranges from $84 million in 2024 to over $336 million by 2027, assuming moderate market penetration.
FAQs
1. When is Ralinepag expected to launch?
Pending regulatory approval, likely around 2024-2025, based on current trial timelines.
2. How does Ralinepag differentiate from existing PAH therapies?
It offers oral administration, potentially improving patient adherence and simplifying treatment regimens.
3. What price point should investors expect for Ralinepag?
While tentative, estimates range from $14,000 to $16,000 per month, aligning with other oral prostacyclins.
4. How will payers influence the drug’s market access?
Payers may negotiate discounts or formulary placements; high-cost therapies face approval hurdles without demonstrated clear benefits.
5. What are the main risks associated with Ralinepag’s commercialization?
Unsuccessful trial results, regulatory delays, and payer resistance could hinder market penetration.
References
[1] Clarivate Analytics. (2022). Pulmonary hypertension market report.
[2] IQVIA. (2022). Global prescription drug sales data.
[3] Reata Pharmaceuticals. (2023). Clinical trial updates.
[4] EvaluatePharma. (2022). Market forecasts for PAH therapies.
[5] FDA. (2021). Pulmonary hypertension drug approvals and guidance documents.
